Protect your website and customers
October is Cyber Security Awareness Month—a perfect opportunity for businesses in Cambridge and Cambridgeshire to strengthen their website security. Granite5 underscores the critical importance of protecting customer data, preventing downtime, and maintaining brand trust. By understanding common threats like malware, DDoS attacks, and phishing, and implementing essential measures such as HTTPS…
Kadans Science Partner breaks ground at new purpose-built commercial science facilities at Merlin Place, North Cambridge
Breaking ground ceremony brings together key stakeholders to celebrate progress in development of new bespoke laboratory facilities Latest facilities extend Kadans’ coverage to include north of Cambridge in addition to site at the Babraham Research Campus
More needs to be done to help the NHS with their sustainability targets
This year’s theme at ReMed was ‘Beyond Disposable: Building a Circular Economy for Medical Devices’ and had a focus on interdisciplinary collaboration. The common theme throughout the conference was the recognition and drive to take practical, immediate actions towards a more circular econom
Stevenage Bioscience Catalyst scoops the Most Successful Science Park (Small) Award at UKSPA40 Anniversary Awards
Congratulations to everyone who took part and for a fantastic and insightful conference from UKSPA, The United Kingdom Science Park Association. Dr Sally Ann Forsyth OBE, CEO of SBC, said: “Stevenage Bioscience Catalyst is truly honoured to win Most Successful Science Park (Small) Award, and for the SBC graduate Autolus Therapeutics to have won Most Successful Company, nominated by SBC as an…
Cambridge reveals innovation blueprint to become world’s leading science and tech region
With the aim to achieve the same level of innovation in the next 10 years as the last 25 years.
Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications
CAL101 is an anti-S100A4 monoclonal antibody (mAb) and Calluna’s lead drug candidate Study demonstrated a favorable safety, pharmacokinetic (PK) and immunogenicity profile CAL101 is now entering Phase 2 clinical development
Ellison Institute of Technology Los Angeles Accelerates Cancer Research with Sapio LIMS
Innovative research institute streamlines operations and enhances collaboration with unified laboratory informatics platformBaltimore, MD, 22 October 2024 – Sapio Sciences, the science-aware™ lab informa
Optibrium demonstrates superior molecular docking method for small molecules and macrocycles
Surflex-Dock structure-based design method outperforms other molecular docking methods for predicting non-cognate ligand pose of macrocyclic compounds Results published Open Access in Journal of Computer-Aided Molecular Design
Award highlights from Costello Medical Consulting
Award winning commitment.
The impact of AI on the event production industry: jobs created and lost
Every event we’ve worked on in the last 12 months has in some way mentioned AI (except Munich Beer Festival and Top Clown UK).
Lily Lin visits Gluetacs Therapeutics
On 15th October 2024, Lily Lin, CEO of Excellence First Enterprise Consultancy, accompanied by Iris Li and Yang Qing from the Lingang Cambridge Network (LCN), visited Gluetacs Therapeutics, a pioneering biotech company and LCN member. Dr. Yang, the founder of Gluetacs, along with his colleagues, warmly welcomed Lily and provided updates on their recent North American business expansion.
Cambridge and GSK announce new five-year collaboration aiming for improved outcomes for patients with hard-to-treat kidney and respiratory diseases
The ambition of the partnership is to treat immune-related diseases more precisely with existing therapies and to rapidly develop new ones.
The economic cost of living with a rare disease across Europe
Although rare diseases affect a relatively small number of patients, collectively there are an estimated 30 million people in Europe living with 6,000-7,000 known rare diseases (RDs).
Price achieved for first indication vs. ASMR
CRA Life Sciences continues its series on leveraging RADAR, its orphan drug data repository, with a focus on PMA trends between ASMR outcomes and average annual treatment costs. The analysis shows a clear correlation between the ASMR rating and the level of price achieved.
Costello Medical Consulting gains B Corp Certification
Leading the way in reinventing business by pursuing purpose as well as profit.
Axol Bioscience acquires Phenocell to advance human disease models
Acquisition expands Axol’s iPSC-derived cell models and service offering to include ophthalmology and dermatologyCAMBRIDGE / EDINBURGH, UK, and GRASSE, FRANCE, 21 October 2024: Axol Bioscience Ltd.
eg technology launch Technology Readiness Level (TRL) assessment
Comprised of both a self-assessment diagnostic tool, through which innovators can assess the Technology Readiness Level of each integral element of their development
Key challenges in the medical device startup landscape
Co-authored by Samantha Shelley, SQMS.
New lab to open to make cutting-edge CAR-T cells in Cambridge
A new state-of-the-art laboratory is set to open at Addenbrooke’s Hospital that will deliver ‘home-grown’ CAR-T cells to help improve treatment for blood cancers.
The rise of the next-Ggn CDMO: strategies for reducing risk and time to market
Creating and producing advanced drug-device combinations, like autoinjectors and pen injectors, requires a depth and breadth of technical expertise.
Costello Medical Consulting Annual Impact Report
Our 2023/24 Annual Impact Report is available to read.
Human skin map gives 'recipe' to build skin and could help prevent scarring
For the first time, researchers have created a single cell atlas of prenatal human skin to understand how skin forms, and what goes wrong in disease.
Yourgene Health Cystic Fibrosis Base assay receives IVDR accreditation
Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, announces that it has received accreditation under the new EU requirements of the in vitro diagnostic regulation (IVDR) for the Yourgene® Cystic Fibrosis Base
Cellular Origins, Fresenius Kabi sign development agreement for scalable automation of cell and gene therapy manufacturing
Companies to develop integration strategies for Fresenius Kabi’s portfolio of Cell Therapy Technologies within Cellular Origins’ Constellation automation platform Initial research to focus on integration of the Cue® Cell Processing System for automated sma
Nuclera closes $75 million USD financing
Series C round led by Elevage Medical Technologies. Funding will accelerate the commercialization of Nuclera’s eProtein Discovery platform, to optimize protein expression and purification workflows within research labs globally.